Managing Hyperkalemia Caused by Inhibitors of the Renin–Angiotensin–Aldosterone System
Top Cited Papers
- 5 August 2004
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351  (6) , 585-592
- https://doi.org/10.1056/nejmra035279
Abstract
Hyperkalemia can develop as a result of treatment with angiotensin-converting–enzyme inhibitors or angiotensin-receptor blockers. This side effect is most common in patients with risk factors such as diabetes mellitus, heart failure, chronic kidney disease, or advanced age. This review explains the pathophysiology and offers clinical guidance for management.Keywords
This publication has 51 references indexed in Scilit:
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Upper Gastrointestinal Tract Injury in Patients Receiving Kayexalate (Sodium Polystyrene Sulfonate) in SorbitolThe American Journal of Surgical Pathology, 2001
- Predictors of the Development of Hyperkalemia in Patients Using Angiotensin-Converting Enzyme InhibitorsAmerican Journal of Nephrology, 2000
- Acute Abdomen With Colonic Necrosis Induced by Kayexalate-SorbitolSouthern Medical Journal, 2000
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- FREQUENCY OF HYPERKALEMIA IN RECIPIENTS OF SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTS WITH BLADDER DRAINAGETransplantation, 1996
- Hyperkalemia as a complication of drug therapyArchives of internal medicine (1960), 1987
- Incidence of hyperkalaemia induced by indomethacin in a hospital population.BMJ, 1985
- Hyperkalemia and Renal Insufficiency: Role of Selective Aldosterone Deficiency and Tubular Unresponsiveness to AldosteroneAmerican Journal of Nephrology, 1981
- Attenuation of Angiotensin II- and III-induced Aldosterone Release by Prostaglandin Synthesis InhibitorsJournal of Clinical Investigation, 1979